Physician profile
Andy Yu
NPI 1427136266
$45,370.67
in general payments reported to CMS, 2019-2025
12 companies · $583 in 2025
The $583 reported for 2025 was more than what 81% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $2,559 · 2021: $6,298 · 2022: $9,240 · 2023: $6,612 · 2024: $4,382 · 2025: $583.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,830 · Food and Beverage: $1,747.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,830.00 |
| Food and Beverage | $1,746.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $43,814.27 | 2019-2025 | Vemlidy |
| Braintree Laboratories, INC. | $409.64 | 2019-2021 | |
| Abbvie INC. | $374.98 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $125.00 | 2025 | Entyvio |
| Madrigal Pharmaceuticals | $124.99 | 2025 | Rezdiffra |
| Phathom Pharmaceuticals, INC. | $124.28 | 2024 | Voquezna |
| Redhill Biopharma INC. | $111.56 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $108.22 | 2019 | |
| Amarin Pharma, INC. | $100.00 | 2019 | |
| Merck Sharp & Dohme LLC | $52.90 | 2019-2023 | Bridion |
| Celgene Corporation | $12.43 | 2021 | |
| Intercept Pharmaceuticals, INC. | $12.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andy Yu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.